SILO Silo Pharma Inc

1,069

$1.45

$0.0024

(0.17%)

Today

Watchers	1,069
52-Wk Low	$1.22
52-Wk High	$6.56

Market Cap	$4.51M
Volume (M)	2,099.00
52-Wk High	$6.56
52-Wk Low	$1.22

Fundamentals

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSDGlobe Newswire • 14 days ago

MedSpray's patented nose-to-brain intranasal technology selected for SPC-15 drug delivery Exclusivity covers multiple indications including anxiety disorders, Alzheimer's disease, and anorexia...

Share to Feed

Silo Pharma Collaborates With Medspray Pharma For Intranasal Technology For Stress Disorder CandidateBenzinga • 14 days ago

Silo Pharma Inc (NASDAQ: SILO) announced a new exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for...

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSDGlobe Newswire • 27 days ago

Study to determine therapeutic relevant dose range and pharmacokinetic to be used for first-in-human trialENGLEWOOD CLIFFS, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO...

Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid ArthritisGlobe Newswire • about 2 months ago

Human tissue study assessed SPU-21's efficiency, optimization, and binding affinity ENGLEWOOD CLIFFS, NJ, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ( the Company...

Short Interest in Silo Pharma, Inc. (NASDAQ:SILO) Decreases By 14.6%Zolmax • about 2 months ago

Silo Pharma, Inc. (NASDAQ:SILO Get Free Report) was the recipient of a significant decrease in short interest in September. As of September 30th, there was short interest totalling 82,100...

Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSDGlobe Newswire • about 2 months ago

Study to test effectiveness of Instructional System Designs (ISD) model for Intranasal SPC-15 ENGLEWOOD CLIFFS, NJ, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ( the...

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDAGlobe Newswire • 3 months ago

Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 ENGLEWOOD CLIFFS, NJ, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq...

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSDGlobe Newswire • 3 months ago

Investigational New Drug (IND) submission to FDA on target for Q1 2024 SPC-15, is a novel Serotonin 4 receptor agonist against stress, developed in conjunction with Columbia University ENGLEWOOD...

Silo Pharma (NASDAQ:SILO) Receives New Coverage from Analysts at LaidlawTicker Report • 3 months ago

Laidlaw assumed coverage on shares of Silo Pharma (NASDAQ:SILO Free Report) in a research report sent to investors on Monday, Marketbeat Ratings reports. The firm issued a buy rating and a...

Silo Pharma initiated with a Buy at LaidlawThe Fly • 3 months ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...